The preventive and therapeutic impact of antiplatelet agents: Past and present

G. F. Gensini, A. A. Conti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Already more than two thousands years ago the Greek physician Hippocrates (V-IV century B.C.) used the extracts of the willow bark to fight fever. At the end of the eighteen hundreds the German chemist Felix Hoffmann obtained acetylsalicylic acid in stable and pure form, and from then on Aspirin (where A is the abbreviation of acetyl and Spir stands for Spirsaure, the German name of salicylic acid) has had enormous diffusion. In 1953 Lawrence Craven reported that he had successfully prescribed aspirin to hundreds of adult male patients for the non-specific prophylaxis of coronary thrombosis. Aspirin is now one of the most well-known drugs in the world, and in the last decades a large body of scientific evidence has appeared with regard to the preventive and therapeutic effects of aspirin and those of other antiplatelet agents. In fact, antiplatelet agents constitute a cornerstone in current pharmacological treatment and prophylaxis. Among the most interesting recent and beneficial areas of impact of aspirin and of other antiplatelet drugs, there are those of stroke and of coronary artery disease, and today targeted pharmacological and non-pharmacological interventions should be carefully combined to deal, preventively and therapeutically, with the cardiovascular epidemic.

Original languageEnglish
Pages (from-to)133-136
Number of pages4
JournalMinerva Medica
Volume100
Issue number2
Publication statusPublished - Apr 2009

Fingerprint

Platelet Aggregation Inhibitors
Aspirin
Therapeutics
Pharmacology
Salix
Coronary Thrombosis
Salicylic Acid
Therapeutic Uses
Names
Coronary Artery Disease
Fever
Stroke
Physicians
Pharmaceutical Preparations

Keywords

  • Aspirin
  • Coronary artery disease
  • History of medicine
  • Platelet aggregation inhibitors
  • Stroke, prevention

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The preventive and therapeutic impact of antiplatelet agents : Past and present. / Gensini, G. F.; Conti, A. A.

In: Minerva Medica, Vol. 100, No. 2, 04.2009, p. 133-136.

Research output: Contribution to journalArticle

Gensini, GF & Conti, AA 2009, 'The preventive and therapeutic impact of antiplatelet agents: Past and present', Minerva Medica, vol. 100, no. 2, pp. 133-136.
Gensini, G. F. ; Conti, A. A. / The preventive and therapeutic impact of antiplatelet agents : Past and present. In: Minerva Medica. 2009 ; Vol. 100, No. 2. pp. 133-136.
@article{7ea5f2b6dd9c4030abf7782e49b28224,
title = "The preventive and therapeutic impact of antiplatelet agents: Past and present",
abstract = "Already more than two thousands years ago the Greek physician Hippocrates (V-IV century B.C.) used the extracts of the willow bark to fight fever. At the end of the eighteen hundreds the German chemist Felix Hoffmann obtained acetylsalicylic acid in stable and pure form, and from then on Aspirin (where A is the abbreviation of acetyl and Spir stands for Spirsaure, the German name of salicylic acid) has had enormous diffusion. In 1953 Lawrence Craven reported that he had successfully prescribed aspirin to hundreds of adult male patients for the non-specific prophylaxis of coronary thrombosis. Aspirin is now one of the most well-known drugs in the world, and in the last decades a large body of scientific evidence has appeared with regard to the preventive and therapeutic effects of aspirin and those of other antiplatelet agents. In fact, antiplatelet agents constitute a cornerstone in current pharmacological treatment and prophylaxis. Among the most interesting recent and beneficial areas of impact of aspirin and of other antiplatelet drugs, there are those of stroke and of coronary artery disease, and today targeted pharmacological and non-pharmacological interventions should be carefully combined to deal, preventively and therapeutically, with the cardiovascular epidemic.",
keywords = "Aspirin, Coronary artery disease, History of medicine, Platelet aggregation inhibitors, Stroke, prevention",
author = "Gensini, {G. F.} and Conti, {A. A.}",
year = "2009",
month = "4",
language = "English",
volume = "100",
pages = "133--136",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - The preventive and therapeutic impact of antiplatelet agents

T2 - Past and present

AU - Gensini, G. F.

AU - Conti, A. A.

PY - 2009/4

Y1 - 2009/4

N2 - Already more than two thousands years ago the Greek physician Hippocrates (V-IV century B.C.) used the extracts of the willow bark to fight fever. At the end of the eighteen hundreds the German chemist Felix Hoffmann obtained acetylsalicylic acid in stable and pure form, and from then on Aspirin (where A is the abbreviation of acetyl and Spir stands for Spirsaure, the German name of salicylic acid) has had enormous diffusion. In 1953 Lawrence Craven reported that he had successfully prescribed aspirin to hundreds of adult male patients for the non-specific prophylaxis of coronary thrombosis. Aspirin is now one of the most well-known drugs in the world, and in the last decades a large body of scientific evidence has appeared with regard to the preventive and therapeutic effects of aspirin and those of other antiplatelet agents. In fact, antiplatelet agents constitute a cornerstone in current pharmacological treatment and prophylaxis. Among the most interesting recent and beneficial areas of impact of aspirin and of other antiplatelet drugs, there are those of stroke and of coronary artery disease, and today targeted pharmacological and non-pharmacological interventions should be carefully combined to deal, preventively and therapeutically, with the cardiovascular epidemic.

AB - Already more than two thousands years ago the Greek physician Hippocrates (V-IV century B.C.) used the extracts of the willow bark to fight fever. At the end of the eighteen hundreds the German chemist Felix Hoffmann obtained acetylsalicylic acid in stable and pure form, and from then on Aspirin (where A is the abbreviation of acetyl and Spir stands for Spirsaure, the German name of salicylic acid) has had enormous diffusion. In 1953 Lawrence Craven reported that he had successfully prescribed aspirin to hundreds of adult male patients for the non-specific prophylaxis of coronary thrombosis. Aspirin is now one of the most well-known drugs in the world, and in the last decades a large body of scientific evidence has appeared with regard to the preventive and therapeutic effects of aspirin and those of other antiplatelet agents. In fact, antiplatelet agents constitute a cornerstone in current pharmacological treatment and prophylaxis. Among the most interesting recent and beneficial areas of impact of aspirin and of other antiplatelet drugs, there are those of stroke and of coronary artery disease, and today targeted pharmacological and non-pharmacological interventions should be carefully combined to deal, preventively and therapeutically, with the cardiovascular epidemic.

KW - Aspirin

KW - Coronary artery disease

KW - History of medicine

KW - Platelet aggregation inhibitors

KW - Stroke, prevention

UR - http://www.scopus.com/inward/record.url?scp=67749110093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749110093&partnerID=8YFLogxK

M3 - Article

C2 - 19390498

AN - SCOPUS:67749110093

VL - 100

SP - 133

EP - 136

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 2

ER -